MESSAGE FROM THE DIRECTOR
Stan Gerson, MD
Director, Case CCC
Joint Message from Drs. Stan Gerson and Brian Bolwell: New CWRU Medical Education Building on Cleveland Clinic Campus
The announcement of a joint medical education building is good news for Cleveland and for the Case CCC. This is a great opportunity to enhance medical education in Cleveland, and reinforces the collaborative spirit that the Case CCC already embraces.
Cleveland Clinic, CWRU Announce Plan to Build New Medical Education Building on Clinic Campus
Impact of Genomics on Cancer Diagnosis and Treatment: Open Drug Policy Forum
Theis just a week away, Monday, June 10. We are extremely pleased that we have over 210 registrants from 13 states participating in this forum. The caliber of the panelists and attendees proves this discussion is timely and very relevant to cancer treatment and health care today.
If you have not already registered, please do so today. As I mentioned we are expecting a full house and ask that all attendees pre-register before June 5. Please help us to ensure our out of town guests feel welcome and have seating in the main room.
CASE CCC IN THE NEWS
University Hospitals Creates Effective Tools to Overcome Barriers to Cancer Clinical Trials
Plain Dealer - Jun 3, 2013
Oncologists know that many patients are not prepared to have a discussion with their doctors about clinical trials, said Dr. Neal Meropol...To that end, Meropol led two studies that sought answers to those problems. The first was a large-scale, randomized trial of a tool called PRE-ACT (Preparatory Education About Clinical Trials). The National Cancer Institute paid for the randomized study. More than 1,200 patients took part at UH and the Cleveland Clinic (both are part of the Case Comprehensive Cancer Center), as well as at Fox Chase Cancer Center in Philadelphia; Karmanos Cancer Center in Detroit; and the Lurie Comprehensive Cancer Center of Northwestern University in Chicago.
African-American Women with Newly Diagnosed Breast Cancer Have Poor Physical Performance
Chemotherapy Advisor - June 3, 2013
In a population of older women with newly diagnosed breast cancer, poor physical performance was highly prevalent, a cross-sectional study of ambulatory oncology clinics within a single academic institution presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting has found. "Relative to non-Hispanic whites, older African-American women were nearly 1.5 times more likely to have poorer physical performance at diagnosis of breast cancer," noted Cynthia Owusu, MD, MS, of Case Western Reserve University and University Hospitals Seidman Cancer Center, Cleveland, OH, and colleagues.
ASCO: Preview of the Prostate Cancer Sessions
Cancer Network - May 30, 2013
Today we're speaking with Dr. Robert Dreicer, chair of the department of solid tumor oncology at Cleveland Clinic's Taussig Cancer Institute. Dr. Dreicer will be discussing some of the prostate cancer highlights of this year's upcoming American Society of Clinical Oncology (ASCO) annual meeting, held May 31 –June 4 in Chicago.
Cleveland Clinic Earns Designation
Helio/HemOnc Today - May 25, 2013
HHT Foundation International recently named Cleveland Clinic as the 15th HHT Center of Excellence in the United States...The new HHT Center, which will fall under Cleveland Clinic's Respiratory Institute, will collaborate with Keith McCrae, MD, a hematologist in the Taussig Cancer Institute who has treated patients with HHT for more than 20 years. McCrae intends to open a new clinical trial for patients with HHT in the next couple months.
Despite Headlines, Role of Statins in Cancer Prevention Far from Proven
Helio/HemOnc Today - May 25, 2013
"It shows up on the news that statins are protective of cancer," Dale R. Shepard, MD, PhD, staff physician in the department of solid tumor oncology at Cleveland Clinic's Taussig Cancer Institute, told HemOnc Today.
Clinicians Offer Insights into Promising Drugs in the Pipeline
Helio/HemOnc Today - May 25, 2013
Perspectives by Patrick C. Ma, MD, MS, Nathan Pennell, MD, PhD, Brian Hill, MD, PhD, Dale R. Shepard, MD, PhD,Manmeet Ahluwalia, MD, FACP, Mitchell Smith, MD, PhD, and James P. Stevenson, MD
Case CCC ACS IRG Pilot Awards
Congratulations to the recent recipients of the Case CCC American Cancer Society Institutional Research Grant pilot awards:
- Linda Cummings, MD, MS: Endoscopic Therapy versus Esophagectomy for Early Esophageal Adenocarcinoma and Barrett's Esophagus with High Grade Dysplasia in the Elderly
- Jennifer Dorth, MD: DNA Repair Gene Expression in Advanced Esophageal Squamous Cell Carcinoma Treated with Definitive 5-FU and Cisplatin-Based Chemoradiotherapy on the Phase III Trial RTOG 9405
- Susan Mazanec, PhD, RN, AOCN: A Family-Centered Intervention for the Transition to Living with Multiple Myeloma as a Chronic Illness
- Carvell Tran Nguyen, MD, PhD: Assessing EphA2 and Ephrin as novel diagnostic and prognostic biomarkers of prostate cancer
- Anirban Sen Gupta, PhD: A Platelet-inspired Nanomedicine Platform for Metastasis-targeted Drug Delivery
- Nicole F. Steinmetz, PhD: Active HER2 immunotherapy using a plant virus-based vaccination platform
These funds are designed to provide seed money to support junior faculty members with an interest in cancer research who do not have national grant support of their own.
Meeting report: Melanoma Initiative Symposium
The Inaugural Mini-Symposium on Melanoma research at Case Western Reserve University, University Hospitals, Cleveland Clinic, and VA Medical Center was held at the Wolstein Research Building Auditorium on March 11, 2013. The symposium was organized by Drs. Nikki Harter,Barbara Bedogni, and Meg Gerstenblith. The conference consisted of 13 oral presentations, and talks were arranged into five oral sessions according to their scientific content. A social event consisting of a box dinner provided the opportunity for basic researchers and clinician scientists to develop new collaborations on melanoma research.
Dr. Stan Gerson, Director of Case Comprehensive Cancer Center and Seidman Cancer Center, welcomed all of the participants to the conference and expressed his enthusiasm in developing a robust research program on melanoma. Dr. Kevin Cooper, Chair of the Department of Dermatology and Director of the Skin Disease Research Center, gave the closing remarks and discussed how this meeting highlighted the importance of integrating clinical expertise with unprecedented advances in knowledge from basic scientists in the quest of understanding melanoma and improving clinical outcomes. [more]
MARK YOUR CALENDARS
Complying with the NIH Public Access Policy
Staff from the CWRU Cleveland Health Sciences Library will present, Complying with the NIH Public Access Policy, on Friday, June 14 from 9-10:15 am in the Wolstein Research Building Auditorium. This seminar will facilitate compliance with the "Revised Policy on Enhancing Public Access to Archived Publications Resulting from NIH-Funded Research." They will outline the submission process and services available on campus to assist researchers in complying with the policy, which requires that all peer-reviewed manuscripts accepted for publication after April 7, 2008, and resulting fully or in part from NIH-funded research, must be deposited to PubMed Central within twelve months of publication. In addition, these articles must be associated with the NIH grant(s) in NCBI's MyBibliography.
St. Baldrick's Foundation Fall 2013 Infrastructure Grants
The St. Baldrick's Foundation announces the opening of Letters of Intent for the Fall 2013 Infrastructure Grant funding category. St. Baldrick's is a volunteer-driven charity committed to funding the most promising research to find cures for childhood cancers and give survivors long and healthy lives.
LOI Deadline: July 2
Request for Proposals for Case CCC Funding for Pilot/Phase I Clinical Trials
The Case CCC is encouraging investigators to submit Letters of Intent for Early Phase Clinical Research Support (EPCRS; former Protocol Specific Research Support) funding. These in-house funds are available for the conduct of early phase clinical trials of relatively short duration. Priority will be given to trials which are developed jointly between UH and CCF with planned accrual at both institutions. (See revised NCI Cancer Center Support Grant EPCRS guidelines, page 43, Section 2.12).
Please submit LOIs and direct questions about the revised guidelines and funding process to Katarzyna Karelus, Case CCC Clinical Research Office, email@example.com, 216-844-4176.
Deadline: July 15
PREVIOUSLY ANNOUNCED OPPORTUNITIES
OCRP Ovarian Cancer Academy Award - Early-Career Investigator
OCRP Resource Development Award
Translational Technology Concept Studies of Circulating Tumor and Endothelial Cells (CTC/CEC)
AACR Scholar-in-Training Awards - Other Conferences and Meetings
Case CCC Protocol Specific Research Support (PSRS)
International Union Against Cancer (UICC) International Cancer Technology Transfer Fellowships
NIH BULLETIN – Notices and Funding Opportunities
HHS Reissues PHS 2013-02 SBIR and STTR Omnibus Grant Solicitations Implementing Venture Capital Provision and SBA Company Registry Requirement of the SBIR/STTR Reauthorization Act of 2011 (NOT-OD-13-071)
NIH to Require Use of Updated Electronic Application Forms for Due Dates on or after September 25, 2013 (NOT-OD-13-074)
NIH Announces an Adjustment to Transition Timeline for Electronic Submission of Multi-Project Applications (NOT-OD-13-075)
Reissue PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])(PA-13-234)
Reissue PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])(PA-13-235)
Chronic Inflammation and Age-related Disease (R01)(PAR-13-233)
Gillian Irwin Todd
11100 Euclid Avenue, Wearn 149
Cleveland, Ohio 44106-5065
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!
Send items to firstname.lastname@example.org.